Comparison of Two Etoposide Initiation Strategies for Severe Hemophagocytic Lymphohistiocytosis (TIC-TAC-SAM)

Comparison of Two Etoposide Initiation Strategies for Severe Hemophagocytic Lymphohistiocytosis in Intensive Care: a Randomized Trial

Hemophagocytic lymphohistiocytosis (HLH) is an immune-mediated disorder characterized by hyperactivation of the immune system, leading to a cytokine storm responsible for organ failures. Consequently, patients with HLH often require intensive care management, where their short-term prognosis is compromised (1-month mortality: 30 to 40%).

Therapeutic management is urgent and consists in treating associated pathologies and employing immunomodulatory therapy. Currently, there are no clear and consistent recommendations for guiding immunomodulatory treatment in HLH due to the lack of high-level evidence studies. Experts recommend corticosteroid therapy for mild forms, whereas etoposide is proposed for severe cases, especially those with organ failures. However, in clinical practice, its use in patients with multi-organ failure is not systematic due to concerns about potential severe side effects and uncertainty regarding the contribution of severe sepsis to the clinical and biological presentation. Consequently, initiation of etoposide is sometimes delayed.

Our hypothesis is that early treatment of severe HLH associated with organ failure using etoposide could reduce organ failures associated with this syndrome. Therefore, we aim to compare two strategies for initiating etoposide in severe HLH in intensive care: an early strategy where etoposide is prescribed at the onset of HLH-related organ failure, and a delayed strategy where etoposide is prescribed only if there is unfavorable progression (or lack of improvement) after treating associated pathologies, associated with corticosteroid therapy.

Study Overview

• Status: Not yet recruiting
• Conditions: Hemophagocytic Lymphohistiocytosis
• Intervention / Treatment: Drug: Etoposide (Early strategy); Drug: Etoposide (Delayed strategy)

Detailed Description

1. Objectives

   Primary Objective: To compare the effect on the evolution of organ failures of two initiation strategies of etoposide in severe HLH in intensive care:

   • An early strategy where etoposide is initiated within 12 hours after inclusion.
   • A delayed strategy where this treatment is initiated only in case of unfavorable evolution (or lack of improvement) after 48 hours.

   The occurrence of an event defined as the onset or worsening of organ failures, evaluated using the modified Sequential Organ Failure Assessment (SOFA) score (excluding the hematologic component, from 0 to 20 points), calculated every 12 hours from Day 1 to Day 5 (Day 0 = inclusion), and then every 24 hours from Day 6 to Day 14. An event will be defined as an increase of at least 1 point for at least two organ systems compared to Day 0. In the delayed arm, the use of rescue etoposide treatment or in case of secondary aggravation during follow-up will also be considered an event.

   Secondary objectives:

   • Evaluate the effect of these 2 strategies on:

     1. Survival
     2. Duration of mechanical ventilation
     3. Duration of catecholamine therapy
     4. Need for renal replacement therapy
     5. Length of stay in the intensive care unit
     6. Length of hospital stay
     7. Proportion of patients receiving etoposide treatment
     8. Cumulative dose of etoposide
     9. Time to initiation of etoposide treatment
     10. Number of patients receiving another immunosuppressive treatment
     11. Normalization of HLH-related biological abnormalities
     12. Evolution of the HScore (probability score for HLH)
     13. Potential side effects attributable to etoposide, such as healthcare-associated infections, incidence of neutropenia, and bleeding events.
     14. Evolution of the SOFA score and modified SOFA score
   • Identify risk factors for mortality in severe HLH in intensive care.
   • Identify and describe comorbidities associated with severe HLH in intensive care, and their prognostic impact.

2. Investigational treatment

   Etoposide is used at a dose of 100 mg/m², administered via slow intravenous infusion over 30 to 60 minutes on Day 0 or Day 2 depending on the arm (early strategy or delayed strategy).

   Patients in the "early strategy" arm will receive etoposide treatment within 12 hours of inclusion.

   In the "delayed strategy" arm, patients will be reassessed 48 hours after inclusion. If there is persistence or deterioration of organ failures (similar or higher modified SOFA score), patients will receive etoposide treatment within 12 hours of this reassessment in the absence of formal contraindications. In cases of rapidly deteriorating clinical status with short-term life-threatening prognosis (defined as an increase of 6 or more points in modified SOFA score), patients may receive rescue treatment (before 48 hours) with etoposide at the discretion of the medical team managing the patient; in such cases, the Day-2 infusion will not be administered. This practice will be exceptional and documented, following consultation with the hotline if possible.

   In the unlikely event of subsequent clinical deterioration from Day 2 to Day 14, etoposide infusion may be considered for patients who did not receive etoposide previously in the "delayed strategy" group. This situation will also be documented.

   Patients in both arms will routinely receive systemic corticosteroid therapy with dexamethasone 10 mg/m² in a daily injection for the duration of the study, unless contraindicated (adjuvant investigational drug).

3. Standard treatment

   In case of persistence of HLH signs, a first (for patients in the "delayed strategy" arm) or subsequent (for patients in both arms) injections of etoposide may be performed during follow-up at the discretion of the patient's care team.

   Other treatments will be:

   • Additional injections of etoposide if signs of hemophagocytic lymphohistiocytosis persist, at least 7 days after the previous administration, if applicable.
   • Treatment of conditions associated with HLH according to current recommendations and after expert consultation where appropriate.
   • In case of clinical deterioration and based on associated conditions, after consultation with experts (hematologist, internist, or immunologist depending on the center), administration of other immunosuppressive treatments may be considered, according to current recommendations and at the discretion of the patient's medical team.
4. Practical procedure Recruitment will take place in the investigational ICUs. Inclusion and exclusion criteria will be verified for all patients admitted to the intensive care unit with suspected secondary HLH. Patients meeting all inclusion criteria and having no exclusion criteria will be invited to participate in the study. Patient information and consent will be handled by the intensivist.

Inclusion and randomization will be conducted through a computer server accessible to all study investigators. This will be a 1:1 randomization into two groups, with stratification based on the SOFA score (<9 or ≥9), prior administration of corticosteroid therapy, and the centers.

The 2 groups will be:

• The "early strategy" group
• The "delayed strategy" group

Data will be collected as part of routine care for HLH management (clinical and biological characteristics, dates of HLH onset and diagnosis, underlying immunosuppression, HLH-associated pathologies, HScore and Henter criteria, immunomodulatory treatments [date, duration], daily assessment of organ support, occurrence of infectious or hemorrhagic events) by the investigator, and recorded in an e-CRF. Data collection will continue up to 14 days post-randomization. SOFA score and modified SOFA score (excluding hematological component) will be calculated and recorded by the investigator every 12 hours from Day 1 to Day 5, then daily from Day 6 to Day 14. Adverse events will be reported from inclusion to Day 14. Vital status will be collected on Day 14 and Day 60, with a maximum follow-up duration of 60 days. A systematic minimal assessment for HLH-associated pathologies will be proposed to each team.

The protocol also includes the establishment of a biobank (serotheca and DNAtheca) at the PRB of Avicenne Hospital.

• Study Type: Interventional
• Enrollment (Estimated): 176
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Julien SCHMIDT, MD; Phone Number: +33 (0)1.48.95.52.41; Email: julien.schmidt@aphp.fr
• Study Contact Backup: Name: Stéphane Gaudry, MD, PhD; Phone Number: +33(0)1.48.95.22.81; Email: stephane.gaudry@aphp.fr

Study Locations

• France
  • Bobigny, France, 93000
    • Intensive Care Unit - Avicenne Hospital, Assistance Publique des Hôpitaux de Paris
    • Contact: Julien SCHMIDT, MD; Phone Number: +33 (0)1.48.95.52.41; Email: julien.schmidt@aphp.fr
    • Contact: Stéphane Gaudry, MD, PhD; Phone Number: +33 (0)1.48.95.22.81; Email: stephane.gaudry@aphp.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Adult patient

• Confirmed diagnosis of HLH:

  • Hscore ≥ 169
  • Diagnosis of HLH established by the multidisciplinary team caring for the patient(A 24/7 hotline will be available in case of diagnostic uncertainty: this will be the direct line to the on-call intensivist at Avicenne Hospital, who can contact the coordinating investigator as needed)
• First episode of HLH
• Admission to intensive care unit

• Presence of one or more organ failures:

  • Circulatory: mBP < 65 mmHg with lactate > 2 mmol/L, or treatment with catecholamines
  • Respiratory: oxygen therapy > 6 L/min or need for non-invasive ventilation, high-flow nasal cannula oxygen therapy, or invasive mechanical ventilation
  • Renal: stage 2 or higher according to KDIGO criteria, defined by a creatinine increase ≥ 2 times baseline, or urine output < 0.5 mL/kg/h for ≥ 12 hours, or initiation of renal replacement therapy
  • Neurological: GCS ≤ 13

Exclusion Criteria:

• Moribund patient with refractory distributive shock: multi-organ failure requiring noradrenaline > 2.5 µg/kg/min and imminent risk of death.
• Inability to administer etoposide within 12 hours.
• Patient treated with etoposide prior to admission to the intensive care unit.
• Hypersensitivity to etoposide or any of its excipients.
• Hypersensitivity or contraindication to dexamethasone or any of its excipients, as described in the package insert for the dexamethasone specialty used in the trial and in the protocol.
• Patient with a history of CAR-T cell therapy.
• Patient developing HLH within 15 days following chemotherapy for cancer or hematologic malignancy.
• Patient not covered by social security.
• Patient under legal guardianship, tutelage, or curatorship.
• Minor patient.
• Pregnant women (positive βhCG), women for whom pregnancy has not been excluded (βhCG not performed in women of childbearing age), or lactating women.
• Recent vaccination with a live attenuated vaccine.
• Participation in another interventional research study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Early strategy; Etoposide treatment will be administered within 12 hours of inclusion.	Drug: Etoposide (Early strategy); early strategy arm: patients will receive etoposide treatment within 12 hours of inclusion.; Other Names: Etoposide is used at a dose of 100 mg/m², administered via slow intravenous infusion over 30 to 60 minutes on Day 0 or Day 2 depending on the arm.
Active Comparator: Delayed strategy; The need for etoposide treatment will be reassessed after 48 hours of management. If organ failure worsens or fails to improve (modified SOFA increase ≥1 point or stable), etoposide will be administered within 12 hours of reassessment. In cases of rapidly deteriorating clinical status with short-term life-threatening prognosis (defined as an increase of 6 or more points in modified SOFA score), patients may receive rescue treatment (before 48 hours) with etoposide at the discretion of the medical team managing the patient; in such cases, the Day-2 infusion will not be administered.	Drug: Etoposide (Delayed strategy); delayed strategy arm: patients will be reassessed 48 hours after inclusion. If there is persistence or deterioration of organ failures (similar or higher modified SOFA score), patients will receive etoposide treatment within 12 hours of this reassessment in the absence of formal contraindications. In cases of rapidly deteriorating clinical status with short-term life-threatening prognosis (defined as an increase of 6 or more points in modified SOFA score), patients may receive rescue treatment (before 48 hours) with etoposide at the discretion of the medical team managing the patient; in such cases, the Day-2 infusion will not be administered. This practice will be exceptional and documented, following consultation with the hotline if possible.; Other Names: Etoposide is used at a dose of 100 mg/m², administered via slow intravenous infusion over 30 to 60 minutes on Day 0 or Day 2 depending on the arm.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Increase of at least 1 point in the modified SOFA score (excluding the hematologic component) for at least two organ systems compared to Day 0. In the delayed arm, the use of rescue etoposide treatment or in case of secondary aggravation during follow-up	The occurrence of an event defined as the onset or worsening of organ failures, evaluated using the modified Sequential Organ Failure Assessment (SOFA) score (excluding the hematologic component, from 0 to 20 points), calculated every 12 hours from Day 1 to Day 5 (Day 0 = inclusion), and then every 24 hours from Day 6 to Day 14. An event will be defined as an increase of at least 1 point for at least two organ systems compared to Day 0. In the delayed arm, the use of rescue etoposide treatment or in case of secondary aggravation during follow-up will also be considered an event.	every 12 hours from Day 1 to Day 5 (Day 0 = inclusion), and then every 24 hours from Day 6 to Day 14

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Length of hospital stay	Length of hospital stay	60 days
Survival	Time to death after inclusion (with a maximum follow-up duration of 60 days)	60 days
Duration of mechanical ventilation	Number of ventilator-free days between inclusion and Day 14. A live discharge from the intensive care unit will be considered equivalent to no mechanical ventilation (event) from the date of discharge. Patients who died before day 14 will be assigned a value of 0 days, corresponding to no days alive without ventilation.	14 days after inclusion
Duration of catecholamine therapy	Number of catecholamine-free days between inclusion and Day 14. A live discharge from the intensive care unit will be considered equivalent to an absence of catecholamines (event) from the date of discharge. Patients who died before D14 will be assigned a value of 0 days, corresponding to an absence of live days without catecholamines.	14 days after inclusion
Need for renal replacement therapy.	Proportion of patients receiving at least one session of renal replacement therapy between inclusion and Day 14. Discharge from intensive care without prior extrarenal purification will be considered a non-event. Death without prior extrarenal purification will be considered a non-event.	14 days after inclusion
Length of stay in the intensive care unit	Length of stay in the intensive care unit	60 days
Proportion of patients receiving etoposide treatment	Proportion of patients receiving a dose of etoposide	60 days
Cumulative dose of etoposide	Cumulative dose of etoposide over the first 14 days, within the total study population and among those receiving at least one dose of treatment	14 days after inclusion
Time to initiation of etoposide treatment	Number of days between inclusion and initiation of etoposide treatment in patients who received etoposide.	60 days
Number of patients receiving another immunosuppressive treatment	Number of patients receiving another immunosuppressive treatment during the intensive care unit stay up to Day 14. Treatment received outside the intensive care unit will not be taken into account.	60 days
Normalization of HLH-related biological abnormalities	Time from inclusion to normalization of fibrinogen (> 2 g/L), decrease in ferritin (< 2000 µg/L), and decrease in triglycerides (< 1.5 mg/dL) during the intensive care unit stay up to Day 14. These blood tests will be performed daily as part of routine care during the period of intensive care.	14 days after inclusion
Evolution of the HScore (probability score for HLH)	HScore at Days 2, 7, and 14. In the event of missing data (particularly for hemophagocytosis), the latest available data will be used	2, 7, and 14 days after inclusion
Potential side effects attributable to etoposide, such as healthcare-associated infections, incidence of neutropenia, and bleeding events	Proportion of patients with at least one healthcare-associated infection, neutropenia acquired after inclusion and its duration, if applicable (defined by PNN <500/mm³), a bleeding event after inclusion requiring transfusion and/or surgery. Patients with neutropenia on admission will be excluded from the neutropenia analysis. Complete blood counts, bleeding events, and transfusions will be monitored daily.	60 days
Evolution of the SOFA score and modified SOFA score.	Delta SOFA at Days 2 and 5, maximum SOFA score, including both SOFA and modified SOFA. The SOFA score will be calculated daily, in accordance with the protocol for the primary endpoint. The maximum SOFA score during the first 14 days will be used.	14 days after inclusion

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris
• Investigators: Principal Investigator: Julien SCHMIDT, MD, Assistance Publique - Hôpitaux de Paris

Study record dates

Study Major Dates

• Study Start (Estimated): April 1, 2026
• Primary Completion (Estimated): December 1, 2029
• Study Completion (Estimated): February 1, 2030

Study Registration Dates

• First Submitted: March 23, 2026
• First Submitted That Met QC Criteria: March 23, 2026
• First Posted (Actual): March 27, 2026

Study Record Updates

• Last Update Posted (Actual): April 23, 2026
• Last Update Submitted That Met QC Criteria: April 20, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: Intensive care unit; Etoposide; Hemophagocytic lymphohistiocytosis; cytokine storm; organe failures
• Additional Relevant MeSH Terms: Pathologic Processes; Systemic Inflammatory Response Syndrome; Inflammation; Lymphatic Diseases; Shock; Histiocytosis, Non-Langerhans-Cell; Histiocytosis; Pathological Conditions, Signs and Symptoms; Hemic and Lymphatic Diseases; Cytokine Release Syndrome; Lymphohistiocytosis, Hemophagocytic; Organic Chemicals; Hydrocarbons; Hydrocarbons, Cyclic; Carbohydrates; Podophyllotoxin; Tetrahydronaphthalenes; Naphthalenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Polycyclic Compounds; Glucosides; Glycosides; Etoposide
• Other Study ID Numbers: APHP230874; 2024-511807-41-01 (Ctis)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No